Cambridge Trust Co. Trims Position in Pfizer Inc. (NYSE:PFE)

Cambridge Trust Co. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 11.0% during the 4th quarter, Holdings Channel reports. The fund owned 73,388 shares of the biopharmaceutical company’s stock after selling 9,053 shares during the period. Cambridge Trust Co.’s holdings in Pfizer were worth $2,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Moneta Group Investment Advisors LLC raised its stake in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank purchased a new position in Pfizer during the fourth quarter valued at approximately $3,150,472,000. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after acquiring an additional 9,393,992 shares during the period. Morgan Stanley boosted its position in Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after purchasing an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $311,238,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.1 %

NYSE PFE opened at $25.41 on Friday. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The business has a fifty day moving average price of $27.14 and a 200 day moving average price of $28.74. The company has a market cap of $143.89 billion, a P/E ratio of 70.51, a P/E/G ratio of 1.15 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.14 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.